To use all functions of this page, please activate cookies in your browser.
my.chemeurope.com
With an accout for my.chemeurope.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
Pertuzumab
Pertuzumab (also called 2C4, formerly known as Omnitarg) is a monoclonal antibody. The first of its class in a line of agents called "HER dimerization inhibitors". By binding to HER2, it inhibits the dimerization of HER2 with other HER receptors, which is hypothesized to result in slowed tumor growth.[1] Omnitarg is currently being developed by Genentech. Additional recommended knowledgeEarly clinical trials of pertuzumab in prostate, breast, and ovarian cancers have been met with limited success.[2] References
|
||||||||||||||||||||||||||||||||||||||||||||||||||
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Pertuzumab". A list of authors is available in Wikipedia. |